Background and objectives: Critically and non-critically ill patients with SARS-CoV-2 infection (Covid-19) may present with higher-than-expected glycemia, even in the absence of diabetes. With this study we aimed to assess glucose, glycemic gap (GlyG) and insulin secretion/sensitivity measures in patients with Covid-19. Materials and Methods: We studied, upon admission, 157 patients with Covid-19 (84: in wards and 73: in intensive care units; ICU); 135 had no history of diabetes. We measured blood glucose upon admission as well as glycated hemoglobin (A1c), plasma insulin and C-peptide. We calculated the GlyG and the Homeostasis Model Assessment 2 (HOMA2) estimates of steady state beta cell function (HOMA2%B) and insulin sensitivity (HOMA2%S). Statistical assessment was done with analysis or the Kruskal-Wallis test. Results: Compared to patients in the wards without diabetes, patients with diabetes in the wards, as well as patients in the ICU (without or with diabetes) had higher admission glycemia. The GlyG was significantly higher in patients without diabetes in the ICU compared to patients without diabetes in the wards, while HOMA2%B based on glucose and insulin was significantly higher in the ICU patients compared to patients in the wards. Of all the parameters, HOMA2%S based on C-peptide/glucose was higher in survivors (n = 133). Conclusions: In our series of patients with Covid-19, a substantial number of patients with and without diabetes had admission hyperglycemia and those who were critically ill may have had compromised insulin secretion and lowered sensitivity to insulin. These findings lend credence to reports of association between Covid-19 and hyperglycemia/secondary diabetes.
Background and objectives: Critically and non-critically illpatients with SARS-CoV-2 infection (Covid-19) may present with higher-than-expected glycemia, even in the absence of diabetes. With this study we aimed to assess glucose, glycemic gap (GlyG) and insulin secretion/sensitivity measures in patients with Covid-19. Materials and Methods: We studied, upon admission, 157 patients with Covid-19 (84: in wards and 73: in intensive care units; ICU); 135 had no history of diabetes. We measured blood glucose upon admission as well as glycated hemoglobin (A1c), plasma insulin and C-peptide. We calculated the GlyG and the Homeostasis Model Assessment 2 (HOMA2) estimates of steady state beta cell function (HOMA2%B) and insulin sensitivity (HOMA2%S). Statistical assessment was done with analysis or the Kruskal-Wallis test. Results: Compared to patients in the wards without diabetes, patients with diabetes in the wards, as well as patients in the ICU (without or with diabetes) had higher admission glycemia. The GlyG was significantly higher in patients without diabetes in the ICU compared to patients without diabetes in the wards, while HOMA2%B based on glucose and insulin was significantly higher in the ICU patients compared to patients in the wards. Of all the parameters, HOMA2%S based on C-peptide/glucose was higher in survivors (n = 133). Conclusions: In our series of patients with Covid-19, a substantial number of patients with and without diabetes had admission hyperglycemia and those who were critically ill may have had compromised insulin secretion and lowered sensitivity to insulin. These findings lend credence to reports of association between Covid-19 and hyperglycemia/secondary diabetes.
Authors: Ioannis Ilias; Edison Jahaj; Stylianos Kokkoris; Dimitrios Zervakis; Prodromos Temperikidis; Eleni Magira; Maria Pratikaki; Alice G Vassiliou; Christina Routsi; Anastasia Kotanidou; Ioanna Dimopoulou Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Gianluca Iacobellis; Carlos A Penaherrera; Luis E Bermudez; Ernesto Bernal Mizrachi Journal: Diabetes Res Clin Pract Date: 2020-05-01 Impact factor: 5.602
Authors: Priscila Bellaver; Ariell F Schaeffer; Diego P Dullius; Marina V Viana; Cristiane B Leitão; Tatiana H Rech Journal: Sci Rep Date: 2019-12-06 Impact factor: 4.379
Authors: Yasmine Ali Abdelhamid; Palash Kar; Mark E Finnis; Liza K Phillips; Mark P Plummer; Jonathan E Shaw; Michael Horowitz; Adam M Deane Journal: Crit Care Date: 2016-09-27 Impact factor: 9.097
Authors: Francesco Rubino; Stephanie A Amiel; Paul Zimmet; George Alberti; Stefan Bornstein; Robert H Eckel; Geltrude Mingrone; Bernhard Boehm; Mark E Cooper; Zhonglin Chai; Stefano Del Prato; Linong Ji; David Hopkins; William H Herman; Kamlesh Khunti; Jean-Claude Mbanya; Eric Renard Journal: N Engl J Med Date: 2020-06-12 Impact factor: 91.245